Barr Trexall
Executive Summary
Promotion of high-dose methotrexate tablets will begin mid-May. DuPont will detail drug to rheumatologists and Barr will handle manufacturing and trade sales. Trexall is approved in 5 mg, 7.5 mg, 10 mg and 15 mg strengths; methotrexate tablets were previously available only in 2.5 mg strength. DuPont and Barr agreed to co-develop and co-promote five products as part of the settlement of a lawsuit over sales of Barr's generic warfarin